Baseline Kidney Function Does Not Affect CV or Renal Outcomes for Canagliflozin

The cardiovascular (CV) and renal outcomes of glucose-lowering therapy with canagliflozin were not affected by baseline levels of kidney function in patients with type 2 diabetes, a new analysis of the CANVAS trial reports.             

Researchers randomized 10,142 patients with type 2 diabetes and estimated glomerular filtration rate (eGFR) >30 mL/min/1.73 m2 to receive either canagliflozin or placebo. The primary outcome of interest was composite CV death, nonfatal myocardial infarction, or nonfatal stroke, as well as other CV and renal outcomes. The current analysis focused on outcomes in patients with chronic kidney disease (eGFR <60 and ≥60 mL/min/1.73 m2) and according to baseline kidney function (eGFR <45, 45 to <60, 60 to <90, and ≥90 mL/min/1.73 m2).  

Canagliflozin consistently prevents CV and renal outcomes across different levels of kidney function @brendonneuen @VladoPerkovic @georgeinstitute https://t.co/eli7AiNQaQ pic.twitter.com/npPMfeZvuJ

— Circulation (@CircAHA) June 25, 2018

According to the study results, canagliflozin did not affect the primary study outcomes in patients with chronic kidney disease (HR=0.70; 95% CI, 0.55 to 0.90) and also in patients with preserved kidney function (HR=0.92; 95% CI, 0.79 to 1.07). The study also reported similar relative effects on CV and renal outcomes across all eGFR subgroups. 

“The effects of canagliflozin on cardiovascular and renal outcomes were not modified by baseline level of kidney function in people with type 2 diabetes and a history or high risk of cardiovascular disease down to eGFR levels of 30 mL/min/1.73 m2,” the authors wrote in their conclusion. “Reassessing current limitations on the use of canagliflozin in chronic kidney disease may allow additional individuals to benefit from this therapy.” 

https://twitter.com/hswapnil/statuses/1011237783405355008

Our paper now parallel published in @CircAHA for #2018ADA!

*Open access*

Cardiovascular & renal outcomes with canagliflozin by baseline kidney function: data from the CANVAS Program#VisualAbstract

Link: https://t.co/uLM6GICvbe

Next: TWEETORIAL summary of the paper (1/9) pic.twitter.com/Qp0SMn5obO

— Brendon Neuen (@brendonneuen) June 25, 2018

The effect of canagliflozin on cardiovascular and renal outcomes is not modified by baseline level of kidney function in T2DM. This reinforces the safety of cana in CKD https://t.co/f3vkNNHHNW

— Belen Perez Pevida (@perezpevida_B) June 26, 2018

How low can you go? Down to eGFR of 30 for #CVD #CKD benefit https://t.co/OnFboroUWn

— Daniel J Drucker (@DanielJDrucker) June 25, 2018

Congrats for an important manuscript ! https://t.co/JsUBpHXdZ1

— Prof Gemma Figtree AM (@gemtreee) July 17, 2018

Well done @brendonneuen !! Major contribution and a terrific background for the CREDENCE and DAPA-CKD https://t.co/ylCLGM1nF7

— Roberto Pecoits-Filho (@pecoitsfilho) June 29, 2018

Source: Circulation